Humacyte (NASDAQ:HUMA) Director Buys $49,999.84 in Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Kathleen Sebelius bought 56,818 shares of Humacyte stock in a transaction that occurred on Tuesday, May 19th. The stock was purchased at an average price of $0.88 per share, with a total value of $49,999.84. Following the purchase, the director directly owned 148,025 shares in the company, valued at $130,262. The trade was a 62.30% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Humacyte Stock Performance

Shares of HUMA opened at $1.05 on Friday. The company has a debt-to-equity ratio of 5.46, a quick ratio of 3.32 and a current ratio of 3.93. The stock has a 50-day moving average of $0.83 and a two-hundred day moving average of $1.04. The stock has a market cap of $233.12 million, a P/E ratio of -1.84 and a beta of 2.31. Humacyte, Inc. has a one year low of $0.55 and a one year high of $2.93.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%. As a group, research analysts predict that Humacyte, Inc. will post -0.32 EPS for the current year.

Institutional Investors Weigh In On Humacyte

A number of institutional investors have recently modified their holdings of HUMA. R Squared Ltd acquired a new stake in shares of Humacyte during the 4th quarter valued at about $25,000. Atom Investors LP acquired a new stake in shares of Humacyte during the 4th quarter valued at about $25,000. Truist Financial Corp acquired a new stake in shares of Humacyte during the 3rd quarter valued at about $28,000. Prudential Financial Inc. acquired a new stake in shares of Humacyte during the 2nd quarter valued at about $28,000. Finally, Financial Advisors Network Inc. acquired a new stake in shares of Humacyte during the 2nd quarter valued at about $28,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on HUMA shares. BTIG Research dropped their price target on Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research note on Friday, April 10th. Wall Street Zen upgraded Humacyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.57.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.